Emmes Coordinates Groundbreaking Stem-Cell Ophthalmology Trial
February 18, 2026 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – CD34+ stem cells, CRO, Emmes, biopharmaceutical, central retinal vein occlusion, ophthalmology, retinal vascular disease
18 February 2026 — Maryland, US — Emmes, a full-service, global Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation – in collaboration with the UC Davis Eye Center, helped coordinate the largest study of its kind using autologous CD34+ stem cells to treat vision loss caused by central retinal vein occlusion (CRVO), a common and often debilitating retinal vascular disease.
CD34+ stem cells are naturally occurring repair cells found in bone marrow that play a key role in vascular healing. In this investigator-initiated study, sponsored by the National Eye Institute, cells were isolated from a patient’s own bone marrow and injected into the eye, with the goal of repairing damaged retinal blood vessels and improving visual function.
A recently completed randomized phase I/II clinical trial demonstrated that intravitreal injection of autologous CD34+ stem cells is well tolerated and feasible, establishing an important safety foundation for future studies. Stem cells were isolated in the GMP (Good Manufacturing Practice) laboratory at the UC Davis Institute for Regenerative Cures. As the largest trial of its kind, this study represents a significant milestone in the development of stem cell–based therapies for retinal vascular disease.
About Emmes
Wherever health challenges arise, Emmes Group is there, advancing science, accelerating innovation, and making a difference worldwide. At Emmes Group, we bring People, Science, and Technology together to deliver meaningful, measurable impact on global health. Our presence across more than 30 countries reflects the scale of our ambition and the purpose that unites us: improving lives through clinical research and innovation. As a group of specialized companies, Emmes, VaxTrials, Veridix, OptymEdge, and Essex Management, we deliver a uniquely integrated model for advancing biomedical research. From vaccine development in Latin America to health informatics for federal agencies, our teams are embedded where the work matters most. Each location represents more than an office, it’s a hub of collaboration, accountability, and innovation, grounded in our core values and driven by our mission. Whether you’re a client, a partner, or a future team member, we invite you to explore how we’re making a difference around the world. Visit: theemmesgroup.com.
